Autologous, allogeneic, in vivo CAR for autoimmune diseases
Chimeric antigen receptor (CAR)-based therapies are emerging for autoimmune diseases (ADs). Early-phase clinical studies in systemic lupus erythematosus (SLE) show encouraging results using autologous, allogeneic, and in vivo CAR T-cell (CAR-T) strategies. This forum compares these three strategies, highlighting clinical design, safety, and efficacy, and explores the translational challenges of in vivo CAR engineering in ADs.
Authors
- Lili Yang (ORCID: https://orcid.org/0000-0001-6568-0404)
- Yan-Ruide Li
Institutions
- University of California, Los Angeles (US)
Publication Details
- Journal
- Trends in Pharmacological Sciences
- Published
- 2025-11-25
- DOI
- https://doi.org/10.1016/j.tips.2025.11.001
- Citations
- 2
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 2.09